Immune Thrombocytopenic Purpura News and Research

RSS
The efficacy of clarithromycin versus levofoxacin-based regimens for H.pylori treatment in naïve patients after the COVID-19 pandemic misuse of antibiotics

The efficacy of clarithromycin versus levofoxacin-based regimens for H.pylori treatment in naïve patients after the COVID-19 pandemic misuse of antibiotics

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

Octapharma extends support for COVID-19 study following promising preliminary data

Octapharma extends support for COVID-19 study following promising preliminary data

FDA approves IND application by Octapharma USA for severe COVID-19 patients

FDA approves IND application by Octapharma USA for severe COVID-19 patients

Scientific evidence for and against causal associations for 47 adverse effects after immunization

Scientific evidence for and against causal associations for 47 adverse effects after immunization

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Positive long-term outcome data for chronic ITP patients treated with rituxamab

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.